Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis

Status Completed

Clinical Trial Summary

Glomerulonephritis is one of the major disease manifestations of systemic lupus erythematosus (SLE). Around one-third of the patients, however, do not respond to conventional immunosuppressive therapy, and they have a high risk of progressing to dialysis-dependent renal failure. Recent studies suggest that immunosuppressive therapy targeted against the calcineurin pathway of T-helper cell, for example, tacrolimus, may be effective in the treatment of primary glomerulonephritis. The investigators plan to an open-label single-arm study the efficacy and safety of long-acting tacrolimus in the treatment of treatment-resistant lupus nephritis. Twenty-five patients with biopsy-proven lupus nephritis will be recruited. They will be treated with oral prednisolone and long-acting tacrolimus for 6 months, followed by 6 months of maintenance steroid and azathioprine. Proteinuria, renal function, clinical and serologic lupus activity will be monitored. This study will explore the potential role of long-acting tacrolimus in resistant lupus nephritis, which has a poor prognosis and no effective treatment at the moment.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01206569
Study type	Interventional
Source	Chinese University of Hong Kong
Contact
Status	Completed
Phase	Phase 4
Start date	September 2010
Completion date	February 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02936375` - The Iguratimod Effect on Lupus Nephritis (IGeLU)	Phase 2
Completed	`NCT03597464` - Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin	Phase 3
Recruiting	`NCT01226147` - Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis	Phase 2
Active, not recruiting	`NCT00569101` - A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis	Phase 2
Terminated	`NCT00368264` - TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )	Phase 2/Phase 3
Completed	`NCT00298506` - Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenolate Mofetil (MMF) in Lupus Nephritis (III/IV/V)	N/A
Completed	`NCT00371319` - Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis	Phase 4
Completed	`NCT00094380` - Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)	Phase 1/Phase 2
Terminated	`NCT04376827` - A Study of Guselkumab in Participants With Active Lupus Nephritis	Phase 2
Completed	`NCT03610516` - Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.	Phase 2
Recruiting	`NCT03526042` - Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis	N/A
Withdrawn	`NCT03859570` - Pentoxifylline in Lupus Nephritis	Phase 4
Completed	`NCT03664908` - Detection of Anti-glomerular Basement Membrane Antibodies (Anti-GBM): a Promising Biomarker for Lupus Nephritis (LN)?	N/A
Completed	`NCT01085097` - A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis	Phase 2
Active, not recruiting	`NCT05704088` - SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients	Phase 4
Not yet recruiting	`NCT06429800` - A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Lupus Nephritis	Phase 1
Recruiting	`NCT02226341` - ACTHar in the Treatment of Lupus Nephritis	Phase 4
Recruiting	`NCT02453997` - Mycophenolic Acid Pharmacokinetics and Pharmacogenomics in Lupus Nephritis	N/A
Completed	`NCT01470183` - Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients	N/A
Terminated	`NCT00089804` - Study of LJP 394 in Lupus Patients With History of Renal Disease	Phase 3